Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Trial in progress: Phase II Study of (early) combination salvage therapy with venetoclax and intensified decitabine in relapsed/refractory AML (VenSwitch)

View Full Paper
Ask AI
Bookmark
Share

Authors

LMLucas MixARAndreas RiedelDSDavid Soekler-Sanchez

Discussion

Loading...

Member takes

Overview

Phase II trial evaluates response rate and bone marrow microenvironment changes in relapsed acute myeloid leukemia patients receiving venetoclax and decitabine.

Key Points

  • Response rate improves with combination therapy for acute myeloid leukemia, enhancing treatment effectiveness.
  • Approximately 85% response rate observed in retrospective data supports the proposed therapy approach.
  • Phase II trial assesses 27 participants receiving venetoclax and decitabine, analyzing response at 28 days.
  • Results may indicate a promising new salvage therapy pathway for patients with poor response to prior treatments.

Cite This Study

Mix et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1e2https://doi.org/10.1182/blood-2025-8253
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Trial in progress: Safety and feasibility of a venetoclax-augmented treosulfan-based reduced intensity conditioning before allogeneic stem cell transplantation in AML, MDS/AML and higher risk MDS (VeStAL)2025
  2. 2Trial in progress: A pilot study of venetoclax to AUGMENT epigenetic modification and chemotherapy in pediatric and young adult patients with relapsed and refractory Acute Myeloid Leukemia2025 · 1 citations
  3. 3A Phase 1B/2A study of weekly decitabine and venetoclax treatment as maintenance therapy in high-risk myeloid malignancy patients post allogeneic stem cell transplantation2025
  4. 4Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial2025
  5. 5The venetoclax combined with metronomic low-dose decitabine and interferon for preventing post-transplant relapse in high-risk MDS and AML patients2025